These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35699319)

  • 61. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A two-stage Bayesian adaptive design for minimum effective dose (MinED)-based dosing-finding trials.
    Mu R; Xu G; Liu G; Pan H
    Contemp Clin Trials; 2021 Sep; 108():106504. PubMed ID: 34303862
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of Bayesian and frequentist group-sequential clinical trial designs.
    Stallard N; Todd S; Ryan EG; Gates S
    BMC Med Res Methodol; 2020 Jan; 20(1):4. PubMed ID: 31910813
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies.
    Kakizume T; Morita S
    Ther Innov Regul Sci; 2014 Mar; 48(2):213-219. PubMed ID: 30227515
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Would the Recommended Dose Have Been Different Using Novel Dose-Finding Designs? Comparing Dose-Finding Designs in Published Trials.
    Silva RB; Yap C; Carvajal R; Lee SM
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250415
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bayesian designs of phase II oncology trials to select maximum effective dose assuming monotonic dose-response relationship.
    Guo B; Li Y
    BMC Med Res Methodol; 2014 Jul; 14():95. PubMed ID: 25074481
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.
    Braun TM; Mercier F
    Stat Med; 2022 Sep; 41(20):3975-3990. PubMed ID: 35662077
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials.
    Zhou Y; Li R; Yan F; Lee JJ; Yuan Y
    Stat Biopharm Res; 2021; 13(2):147-155. PubMed ID: 34249223
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Bayesian evaluation of enrolling additional patients at the maximum tolerated dose in Phase I trials.
    Gönen M
    Contemp Clin Trials; 2005 Apr; 26(2):131-40. PubMed ID: 15837436
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A Bayesian sequential design with binary outcome.
    Zhu H; Yu Q; Mercante DE
    Pharm Stat; 2017 May; 16(3):192-200. PubMed ID: 28251815
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bayesian group sequential designs for phase III emergency medicine trials: a case study using the PARAMEDIC2 trial.
    Ryan EG; Stallard N; Lall R; Ji C; Perkins GD; Gates S
    Trials; 2020 Jan; 21(1):84. PubMed ID: 31937351
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Shotgun-2: A Bayesian phase I/II basket trial design to identify indication-specific optimal biological doses.
    Chen X; Zhang J; Jiang L; Yan F
    Stat Methods Med Res; 2023 Mar; 32(3):443-464. PubMed ID: 36217826
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
    Thall PF; Lee SJ
    Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Uniformly most powerful Bayesian interval design for phase I dose-finding trials.
    Lin R; Yin G
    Pharm Stat; 2018 Nov; 17(6):710-724. PubMed ID: 30066466
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Design considerations for dose-expansion cohorts in phase I trials.
    Iasonos A; O'Quigley J
    J Clin Oncol; 2013 Nov; 31(31):4014-21. PubMed ID: 24101039
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.